|1.||Cherrington, Julie M: 4 articles (08/2003 - 01/2002)|
|2.||Abdollahi, Amir: 3 articles (04/2008 - 07/2003)|
|3.||Huber, Peter E: 3 articles (04/2008 - 07/2003)|
|4.||Kitajima, Masaki: 3 articles (01/2006 - 01/2005)|
|5.||Kubota, Tetsuro: 3 articles (01/2006 - 01/2005)|
|6.||Ullrich, Axel: 3 articles (08/2005 - 02/2004)|
|7.||Ellis, L M: 3 articles (10/2001 - 01/2000)|
|8.||McMahon, G: 3 articles (10/2001 - 08/2000)|
|9.||Ohwada, Michitaka: 2 articles (11/2008 - 03/2005)|
|10.||Takei, Yuji: 2 articles (11/2008 - 03/2005)|
11/01/2004 - "To evaluate the biologic effects of SU6668 in patients with solid tumors using comprehensive measures of pharmacokinetics (PK), functional imaging, and tissue correlative studies. "
01/01/2006 - "Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells."
03/20/2005 - "inoculation of tumor cells, SU6668 was orally administered 6 times weekly at a daily dose of 100 mg/kg or 400 mg/kg. The SU6668-administered group and the vehicle-administered control group were compared for the number of tumor vascular endothelial cells, weight of peritoneally disseminated tumors, amount of ascitic fluid and survival time. "
01/15/2005 - "At 6 hours post therapy, SU6668 reduced VEGFR and PDGFR phosphorylation in the tumors by 50% and 92%, respectively, but levels rebounded beyond the baselines by 24 hours. "
01/15/2005 - "The dose-dependent effects of SU6668 on angiogenesis and tumor growth were investigated in orthotopic L3.6pl pancreatic tumors. "
08/01/2000 - "Furthermore, intravital multifluorescence videomicroscopy of C6 glioma xenografts in the dorsal skinfold chamber model revealed that SU6668 treatment suppressed tumor angiogenesis. "
02/01/2005 - "To assess the effects of SU6668 on overall survival, C6 glioma cells were implanted stereotactically into the brains of 24 additional animals and treatment was initiated on Day 7. In both the immediate and delayed experimental setting, SU6668 treatment resulted in a significant reduction of total and functional tumor vessel densities (both p < 0.05), reflecting a suppression of angiogenesis and impairment of tumor perfusion. "
08/01/2000 - "administration of SU6668 in athymic mice resulted in significant growth inhibition of a diverse panel of human tumor xenografts of glioma, melanoma, lung, colon, ovarian, and epidermoid origin. "
02/01/2005 - "The goal of this study was to determine the effects of SU6668, a polyvalent receptor tyrosine kinase inhibitor against vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor-beta, and fibroblast growth factor-1 on tumor growth, angiogenesis, and microcirculation in an orthotopic malignant glioma model. "
|3.||Breast Neoplasms (Breast Cancer)
10/15/2002 - "The therapeutic efficacy of combined antiangiogenic and immune therapy was tested against weakly immunogenic and highly metastatic 4T1 breast tumor using SU6668, an angiogenesis inhibitor and recombinant murine (rm) B7.2-IgG fusion protein, an immunostimulator. "
01/01/2013 - "SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression."
10/15/2002 - "Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein."
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|5.||Neoplasm Metastasis (Metastasis)
10/01/2001 - "Using double-fluorescence immunohistochemistry, phosphorylated Erk and Akt were constitutively expressed in ECs in liver metastases in untreated mice, but SU6668 blocked activation of these signaling intermediates. "
07/01/2006 - "To study the effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice. "
07/01/2006 - "The growth and metastasis of human gastric cancer implanted in SCID mice were significantly inhibited in SU6668 group and combined group, especially in combined group. "
07/01/2006 - "[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice]."
01/01/2014 - "Results showed that metastasis rates in SU6668+5-Fu group, SU6668 group, 5-Fu group decreased obviously (P<0.01). "
|1.||SU 5416 (SU5416)
|3.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|4.||glucuronyl glucosamine glycan sulfate (Vessel)
|5.||Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)
|8.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|9.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|10.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Transplantation (Transplant Recipients)